Nature Medicine Study Describes a Novel Senolytic Molecule that Slows the Progression of Osteoarthritis
April 24, 2017
SAN FRANCISCO, April 24, 2017 /PRNewswire/ — UNITY Biotechnology, Inc. announced today the publication of new research in the journal Nature Medicine demonstrating that the selective elimination of senescent cells with a drug may delay, prevent, or even reverse the progression of osteoarthritis (OA)
UNITY Biotechnology Announces $116 Million Series B Financing
October 27, 2016
SAN FRANCISCO, Oct. 27, 2016 /PRNewswire/ — UNITY Biotechnology, Inc. (“UNITY”), a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Ascentage Pharma and UNITY Biotechnology Announce Collaboration for the Development of Senolytic Healthspan Therapies
April 24, 2016
SAN FRANCISCO, April 24, 2016 /PRNewswire/ — Ascentage Pharma, a clinical-stage biopharmaceutical company focused on apoptosis-targeted oncology drug discovery and development, and UNITY Biotechnology, a San Francisco-based biopharmaceutical company focused on the development of medicines to improve healthspan, announced a worldwide collaboration to develop senolytic treatments for age-related disease.
Unity Biotechnology Launches with a Focus on Preventing and Reversing Diseases of Aging
February 03, 2016
SAN FRANCISCO–(BUSINESS WIRE)–Unity Biotechnology today announced that it is developing medicines to treat and eliminate age-related diseases and increase healthspan, or the amount of time an individual lives in good health. Unity‘s initial funding has been led by founding investor ARCH Venture Partners, with significant contributions from Venrock, WuXi, Mayo Clinic, Unity’s management team and others.